ArticleOncogenesis2016
The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells.
Article in Oncogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- A novel gene signature based on Like-Smith family members-related genes for predicting the prognosis of hepatocellular carcinoma.Translational cancer research · 2026Article
- The Lsm1-7 complex couples 3'-end protection to histone H4 acetylation to maintain mRNA homeostasis in Fusarium graminearum.Nucleic acids research · 2026Article
- Article
- Identification and validation of hub m7G-related genes and infiltrating immune cells in osteoarthritis based on integrated computational and bioinformatics analysis.BMC musculoskeletal disorders · 2025Article
- Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors.Journal of pharmaceutical analysis · 2024Review
- Sm-like 5 knockdown inhibits proliferation and promotes apoptosis of colon cancer cells by upregulating p53, CDKN1A and TNFRSF10B.World journal of gastrointestinal oncology · 2024Article
- Predicting the risk of primary Sjögren's syndrome with key N7-methylguanosine-related genes: A novel XGBoost model.Heliyon · 2024Article
- The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.Medical oncology (Northwood, London, England) · 2023Article
- LSM2 is associated with a poor prognosis and promotes cell proliferation, migration, and invasion in skin cutaneous melanoma.BMC medical genomics · 2023Article
- Identification of LSM family members as potential chemoresistance predictive and therapeutic biomarkers for gastric cancer.Frontiers in oncology · 2023Article
- Correlation between LSM1 Expression and Clinical Outcomes in Glioblastoma and Functional Mechanisms.International journal of genomics · 2023Article
- Expression profile and prognostic values of LSM family in skin cutaneous melanoma.BMC medical genomics · 2022Article
- mTOR Contributes to the Proteome Diversity through Transcriptome-Wide Alternative Splicing.International journal of molecular sciences · 2022Article
- Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer.Journal of cellular and molecular medicine · 2022Article
- Processing body (P-body) and its mediators in cancer.Molecular and cellular biochemistry · 2022Review
- Article
- Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- An Immune-Related Genetic Feature Depicted the Heterogeneous Nature of Lung Adenocarcinoma and Squamous Cell Carcinoma and Their Distinctive Predicted Drug Responses.Oxidative medicine and cellular longevity · 2022Article
- m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma.Frontiers in pharmacology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The cancer-associated Sm-like (CaSm) oncogene is overexpressed in 87% of human pancreatic tumor samples and CaSm knockdown has demonstrated therapeutic efficacy in murine models of pancreatic cancer. Evidence indicates that CaSm modulates messenger RNA degradation; however, its target genes and the mechanisms by which CaSm promotes pancreatic cancer remain largely unknown. Here, we demonstrate that the CaSm overexpression alters several hallmarks of cancer-including transformation, proliferation, chemoresistance and metastasis. Doxycycline-induced CaSm expression enhanced proliferation and both anchorage-dependent and -independent growth of the human Panc-1 cells in vitro. CaSm induction decreased gemcitabine-induced cytotoxicity and altered the expression of apoptotic regulation genes, including Bad, E2F1 and Bcl-XL. CaSm-overexpressing Panc-1 cells were twofold more migratory and fourfold more invasive than the driver controls and demonstrated characteristics of epithelial-to-mesenchymal transition such as morphological changes and decreased E-cadherin expression. CaSm induction resulted in changes in RNA expression of metastasis-associated genes such as MMP1, SerpinB5, uPAR and Slug. Using a murine model of metastatic pancreatic cancer, injection of CaSm-induced Panc-1 cells resulted in a higher abundance of hepatic metastatic lesions. Overall, CaSm overexpression contributed to a more aggressive cancer phenotype in Panc-1 cells, further supporting the use of CaSm as a therapeutic target against pancreatic cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.